Effectiveness of (IL)-17A to other biologics in patients with psoriasis

[Fred]

This study compared the effectiveness of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis.

Quote:

---

Background:
Clinical trials study treatment outcomes under stringent conditions, capturing incompletely the heterogeneity of patient populations and treatment complexities encountered in real-world practice.

Objectives:
To compare the effectiveness of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis.

Methods:
The Psoriasis Study of Health Outcomes (PSoHO) is an ongoing 3-year observational cohort study in adults with chronic moderate-to-severe plaque psoriasis initiating or switching to a new biologic. Primary study endpoint is proportion of patients achieving 90% improvement in Psoriasis Area and Severity Index (PASI 90) and/or static Physician Global Assessment (sPGA) 0/1 at Week 12 (W12) in the anti-IL-17A cohort (ixekizumab [IXE], secukinumab) versus all other approved biologics. Secondary outcomes include proportion of patients who achieve PASI 75/90/100, absolute PASI scores ≤5, ≤2 and ≤1, Dermatology Life Quality Index (DLQI) score of 0/1 at W12 between the two cohorts and among the individual biologics. Comparative effectiveness analyses were conducted using Frequentist Model Averaging (FMA), a novel causal inference machine learning approach. Missing data for binary outcomes were imputed as non-response.

Results:
Patient profiles in the anti-IL-17A cohort and other biologics cohort were similar, with more frequent comorbid psoriatic arthritis and less frequent exposure to conventional treatments in the patients receiving anti-IL17A biologics. At W12, 71.4% of patients who received an anti-IL-17A biologic achieved PASI 90 and/or sPGA 0/1 compared to 58.6% of patients who received other biologics (odds ratios [OR], 1.9; 95% confidence intervals [CI], [1.6, 2.4]). Similar findings were observed for secondary outcomes.

Conclusions:
These results reflect the high efficacy and early onset of skin clearance of IL-17A inhibitors observed in randomized clinical trials and confirm the effectiveness of anti-IL17A biologics in the real-world setting.

Source: onlinelibrary.wiley.com

*Early view funding unknown

[thread=77]

[KatT]

Interesting! Wonder if they will do a similar study for PSA.  I find it more difficult to treat than the psoriasis.

I did take Cosentyx buuut didn't see improvement in PSA.  As for it's effectiveness on psoriasis, I was also taking azathioprine at the same time so it's hard to tell which medication was more efficient.

[Caroline]

Agreed KatT and this even while IL-17 is known as an indicator for Psoriatic Arthritis, where treatments of IL-17 often seem to work.
You are an exception with the Cosentyx, which has a good name for treating Psoriatic Arthritis.

While Psoriatic Arthritis is seen in 30% of the Psoriasis patients, it doesn’t seem to have an equal 30% in research.

[Fred]

Interesting! Wonder if they will do a similar study for PSA.  I find it more difficult to treat than the psoriasis.

I would imagine so, my doctor has suggested it as my next treatment.

[thread=7418]